← Holders
Acuta Capital Partners, LLC
What Acuta Capital Partners, LLC reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1582844 · Filed Nov 16, 2026
- Positions
- 35
- Reported value
- $131.6M
- Opened
- 12
- Closed
- 0
- Other managers included
- 0
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
Quarters on file
- Sep 30, 2025$96.8M28 positions
- Dec 31, 2025$147.3M30 positions
- Mar 31, 2026$141.8M27 positions
- Jun 30, 2026$143.5M23 positions
- Sep 30, 2026$131.6M35 positions
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
PRAXPraxis Precision Medicines, Inc. | 84.2K | +1.7% | $24.5M | 18.6% |
WHWKWhitehawk Therapeutics, Inc. | 4.7M | ±0% | $17.6M | 13.4% |
TNGXTango Therapeutics, Inc. | 409.5K | +4.8% | $10.2M | 7.8% |
FDMT4D Molecular Therapeutics, Inc. | 535.1K | +5.4% | $7.7M | 5.8% |
ARGXArgenx SE | 5.6K | +18.1% | $5.3M | 4% |
AVBPArriVent BioPharma, Inc. | 170.9K | −21.9% | $5.2M | 3.9% |
SRZNSurrozen, Inc. | 152.5K | −12.0% | $4.9M | 3.7% |
VOGXVogenx, Inc. | 213.2K | New | $4.9M | 3.7% |
DRUGBright Minds Biosciences Inc. | 93.2K | +0.4% | $4.6M | 3.5% |
OCULOcular Therapeutix, Inc | 574.5K | +7.9% | $4.4M | 3.3% |
SLNSilence Therapeutics plc | 393.6K | New | $4.3M | 3.3% |
TSHATaysha Gene Therapies, Inc. | 691.8K | +23.1% | $3.4M | 2.6% |
AVLNAvalyn Pharma Inc. | 114.7K | −0.2% | $3.3M | 2.5% |
AVTXAvalo Therapeutics, Inc. | 186.3K | ±0% | $2.9M | 2.2% |
MLTXMoonLake Immunotherapeutics | 216.6K | +0.4% | $2.5M | 1.9% |
IRDOpus Genetics, Inc. | 514.1K | New | $2.5M | 1.9% |
NERVMinerva Neurosciences, Inc. | 729.5K | +2.8% | $2.4M | 1.9% |
LBRXLB Pharmaceuticals Inc | 52.7K | +82.3% | $2M | 1.5% |
| 1K | New | $2M | 1.5% | |
ARTVArtiva Biotherapeutics, Inc. | 260.4K | ±0% | $1.9M | 1.4% |
AMLXAmylyx Pharmaceuticals, Inc. | 63K | −62.6% | $1.8M | 1.4% |
RVMDRevolution Medicines, Inc. | 8.2K | New | $1.7M | 1.3% |
IRLAIRulya Therapeutics Inc. | 52.9K | New | $1.6M | 1.2% |
ROIVRoivant Sciences Ltd. | 41.5K | New | $1.5M | 1.2% |
DSGNDesign Therapeutics, Inc. | 115.4K | −59.2% | $1.5M | 1.1% |
UTHRUnited Therapeutics Corp | 2.2K | +0.7% | $1.2M | 0.9% |
CTNMContineum Therapeutics, Inc. | 89.8K | +42.4% | $1.2M | 0.9% |
ORICOric Pharmaceuticals, Inc. | 87.9K | New | $1.2M | 0.9% |
ERASErasca, Inc. | 67.5K | −74.5% | $990.2K | 0.8% |
ANTXAN2 Therapeutics, Inc. | 142.1K | New | $755.7K | 0.6% |
ADILAzora Therapeutics, Inc. (DE) | 130K | New | $521.2K | 0.4% |
STROSutro Biopharma, Inc. | 25.3K | −90.6% | $407.4K | 0.3% |
EQEquillium, Inc. | 183K | New | $297.4K | 0.2% |
CMPXCompass Therapeutics, Inc. | 251K | −57.8% | $261K | 0.2% |
STOKStoke Therapeutics, Inc. | 5.8K | New | $150K | 0.1% |